| TDY |
Report |
Non-GAAP diluted EPS |
BEAT |
pred ~$5.86 vs. cons $5.793; Day-1 residual -1%; 5-day residual -2% |
MEDIUM |
| TDY |
Report |
Revenue |
IN-LINE |
pred ~$1.595B vs. cons $1.580B; Day-1 residual -1%; 5-day residual -2% |
MEDIUM |
| TDY |
Report |
Organic growth |
BEAT |
pred ~4.4% vs. cons 4.0%; Day-1 residual -1%; 5-day residual -2% |
MEDIUM |
| TDY |
Guide |
Non-GAAP EPS (Q3 FY2026) |
UNCHANGED |
guide ~$5.95 vs. cons $6.006; Day-1 residual -1%; 5-day residual -2% |
LOW |
| TDY |
Guide |
Non-GAAP EPS (FY2026) |
UNCHANGED |
guide ~$24.15 vs. cons $24.195; Day-1 residual -1%; 5-day residual -2% |
MEDIUM |
| TDY |
Guide |
Defense orders / book-to-bill (H2 FY2026) |
BETTER |
guide above 1.0; no reliable numeric consensus; Day-1 residual -1%; 5-day residual -2% |
MEDIUM |
| TDY |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.0% |
— |
LOW |
| TDY |
Return |
5-day cumulative residual |
-2.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — limited forward-estimate upside |
LOW |